Most of our patients begin to see initial reductions in symptoms within 3-6 months of treatment, with long-term reduction in symptoms and independence from medication after 2 years of treatment at our dosages.
Studies at lower dosages show that those who complete 3 years of treatment often result in life-long remission of their allergies.
Biscuit Health is actively exploring ways to reduce treatment time to make allergy care more accessible and affordable for Canadians. We plan on publishing our own studies of how we are able to go above and beyond current industry success rates by taking a patient-centric and data-backed approach.
Sources:
Study: | Summary: | Key Findings: |
SLIT results in a 32% reduction in combined symptom & medication scores after 3-6 months of treatment. | Primary efficacy results demonstrated a significant (P < .0001) and clinically relevant (32%) reduction in the combined symptom and medication score compared with placebo after 3 to 6 months of SLIT. Significantly better rhinoconjunctivitis quality-of-life scores (P < .0001) and the patient's own overall assessment of his or her health status, including the visual analog scale score (Euro Quality of Life Visual Analogue Scale; P = .0025), were also demonstrated. | |
Symptom reduction can be see as early as after 14-weeks of SLIT treatment. | SLIT with a mixture of D.f. and D.p. extract is an effective and safe treatment for patients with house dust mite-induced AR. Its onset of action can be observed as early as 14 weeks after treatment. | |
4 years of immunotherapy treatment with a 3x per week dosage totalling 390µg of cumulative antigen annually can result in permanent relief.
NOTE: Biscuit delivers 7x per week dosage totalling ~900µg of cumulative antigen annually in order to reduce treatment time to ~1.5 to 2 years. | Under the present conditions, it can be suggested that a 4-year duration of SLIT is the optimal choice because it induces a long-lasting clinical improvement similar to that seen with a 5-year course and greater than that of a 3-year vaccination. | |
3 years of immunotherapy treatment resulted in long-lasting significant effects under a dosage of 6,200 BAU per day of antigen.
NOTE: Biscuit delivers 10,000 BAU per day of antigen in order to reduce treatment time to ~1.5 to 2 years. | The mean rhinoconjunctivitis daily symptom score was reduced by 25% to 36% (P ≤ .004) in the grass allergy immunotherapy tablet group compared with the placebo group over the 5 grass pollen seasons covered by the trial. The rhinoconjunctivitis DMS was reduced by 20% to 45% (P ≤ .022 for seasons 1-4; P = .114 for season 5), and the weighted rhinoconjunctivitis combined score was reduced by 27% to 41% (P ≤ .003) in favor of active treatment. The percentage of days with severe symptoms during the peak grass pollen exposure was in all seasons lower in the active group than in the placebo group, with relative differences of 49% to 63% (P ≤ .0001). Efficacy was supported by long-lasting significant effects on the allergen-specific antibody response. No safety issues were identified. |